Genetic Testing Helped Find Causes In Some Epilepsies
This study built a real-world database of 167 people with epilepsy and examined how often genetic testing identified a diagnosis.
This hub covers epilepsy genetics: how gene changes can contribute to seizures (often in children). We translate studies on testing, results like VUS, and what findings may change for care.
No. It’s common in pediatrics, but adults can benefit from genetic testing, too, especially with unclear diagnosis or family history.
Sometimes. For certain conditions, results can guide medication choice, diet therapies, or referral decisions.
It usually means “not enough evidence yet.” It shouldn’t be treated as a definite cause, but it can be reclassified over time.
Not necessarily. Testing can miss some variants, and new gene links are still being discovered.
This study built a real-world database of 167 people with epilepsy and examined how often genetic testing identified a diagnosis.
This paper is a case report.
Researchers looked at a rare inherited neurometabolic disorder called succinic semialdehyde dehydrogenase deficiency (SSADHD), which is caused by variants in the ALDH5A1 gene.
Researchers tested whether a risk-stratified care pathway could be added to routine epilepsy care for adults who also had clinically relevant symptoms of depression or anxiety.
This paper was a systematic review, which means the authors gathered and summarized earlier studies rather than testing one new group of patients.
This study was a systematic review and meta-analysis.
This study looked at 31 children seen at one tertiary referral center in Kazakhstan for epilepsy or epilepsy-associated neurodevelopmental disorders who were found to have genetic findings considered clinically relevant or potentially relevant.
This study looked at whether epilepsy in children with autism spectrum disorder (ASD) was associated with results from neurologic evaluations, including EEG, brain imaging, genetic testing, and developmental assessments.
This paper combined results from 20 studies of fenfluramine in people with developmental and epileptic encephalopathies (DEEs), a group of severe epilepsy conditions.